CALGB 40601: Randomized Phase III Trial of Paclitaxel Combined With Trastuzumab, Lapatinib, or Both As Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer
Demographics (3)
- Age_on_Study - Age consented to study (phv00375360.v1.p1)
- Sex - Gender of participant (phv00556151.v1.p1)
- Sex - Gender of participant (phv00504359.v1.p1)
Disease Events (21)
- AFFECTION_STATUS - Case control status of the subject for breast cancer (phv00504360.v2.p1)
- efs_event_updated - Event free survival event (event is breast cancer relapse after surgery, second primary malignant neoplasm, or death without recurrence) 9-yr. follow-up (phv00504363.v1.p1)
- efs_stat - Event free survival status (event is either death by any cause or recurrence - local or distant) (phv00426548.v1.p1)
- efs_time - Time to first event (event is either death by any cause or recurrence - local or distant) (phv00426547.v1.p1)
- efs_time_updated - Time from randomization to first event (event is breast cancer relapse after surgery, second primary malignant neoplasm, or death without recurrence) 9-yr follow-up (phv00504362.v1.p1)
- ER_Status - Estrogen Receptor Status (phv00375364.v1.p1)
- pCR_Breast - Pathologic Complete Response in Breast (phv00375369.v1.p1)
- pCR_breast_axilla - Pathologic Complete Response in Breast and Axilla (phv00375370.v1.p1)
- PR_Status - Progesterone Recptor Status (phv00375365.v1.p1)
- PRIMARY_TUMOR_LOCATION - Primary tumor location (phv00375378.v2.p1)
- Stra2_Stage - Stage (phv00375362.v1.p1)
- Stra3_HR_Status - Hormonal Receptor Status (phv00375363.v1.p1)
- surv_mos - Survival time in months (phv00426549.v1.p1)
- surv_stat - Survival status (event is death) (phv00426550.v1.p1)
- TILs - Percentage of stromal tumor infiltrating lymphocytes (phv00504361.v2.p1)
- Tumor_Size_PE - Tumor Size Pretreatment (phv00375368.v1.p1)
- TUMOR_STAGE - Tumor stage of sample (phv00375381.v2.p1)
- Tumor_Subtype_PAM50 - Tumor subtype by PAM50 (phv00375382.v2.p1)
- Tumor_Subtype_PAM50_v2 - Updated tumor subtype by PAM50 (phv00426551.v2.p1)
- TUMOR_TREATMENT - Type of tumor treatment for sample (phv00375379.v2.p1)
- Tx_arm - Treatment Arm (phv00375359.v1.p1)
Race and Ethnicity (1)
- Race - Race of participant (phv00375361.v1.p1)
Reproductive Health (1)
- Meno_Status - Menopause status (phv00375367.v1.p1)
Other (19)
- ANALYTE_TYPE - Analyte Type (phv00375373.v2.p1)
- CONSENT - Consent group as determined by DAC (phv00375349.v1.p1)
- ECOG_PS - Performance level of participant (phv00375366.v1.p1)
- fu_mos - Months of follow up (phv00426546.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00375375.v2.p1)
- IS_TUMOR - Tumor status (phv00375374.v2.p1)
- PRIMARY_METASTATIC_NORMAL - Primary tumor, metastatic tumor, or normal blood (phv00375376.v2.p1)
- Sample_Body_Site - Body site where sample was collected (phv00375377.v2.p1)
- SAMPLE_ID - De-identified Sample ID (phv00375372.v2.p1)
- SAMPLE_ID - Sample ID (phv00375354.v2.p1)
- SAMPLE_SOURCE - Source repository where samples originate (phv00375355.v2.p1)
- Sequencing_Center - Name of the center which conducted sequencing (phv00375383.v2.p1)
- SOURCE_SAMPLE_ID - Sample ID used in the Source Repository (phv00375356.v2.p1)
- SOURCE_SUBJECT_ID - Subject ID used in the Source Repository (phv00375351.v1.p1)
- SUBJECT_ID - De-identified Subject ID (phv00375358.v1.p1)
- SUBJECT_ID - Subject ID (phv00375348.v1.p1)
- SUBJECT_ID - Subject ID (phv00375353.v2.p1)
- SUBJECT_SOURCE - Source repository where subjects originate (phv00375350.v1.p1)
- Tumor_Collection - Timing of tumor collection, pre or post surgery (phv00375380.v2.p1)